Why the study?
To investigate the mechanism of magnetic nanoparticles on AF and the effect of NIPA-co-MN on AF treatment.
Does injection of n-isopropylacrylamide magnetic nanoparticles affect cardiac autonomic nerve remodeling and electrophysiological parameters in a beagle model of atrial fibrillation?
Does injection of n-isopropylacrylamide magnetic nanoparticles affect cardiac autonomic nerve remodeling and electrophysiological parameters in a beagle model of atrial fibrillation?
Magnetic nanoparticles may modulate cardiac autonomic nerve remodeling and alter electrophysiological properties in atrial fibrillation, potentially offering a novel therapeutic target.
May modulate lncRNA in canine AF models; leaves open human translation and efficacy.
It aimed to investigate the mechanism of magnetic nanoparticles (MNPs) on atrial fibrillation and effect of n-isopropyl acrylamide coated MNPs (NIPA-co-MN) on the treatment of atrial fibrillation. Ten beagles weighing 20 - 25 kg were randomly divided into test group and control group. Dogs with atrial fibrillation were set as test group, and non-atrial fibrillation dogs as control group. The expression of long non-coding RNA (lncRNA) differentially expressed in the right anterior adipose pad in atrial fibrillation and non-atrial fibrillation dogs was detected by high-throughput sequencing. The relationship between lncRNA and cardiac autonomic nerve remodeling (CANR) was explored. In addition, 20 beagles weighing 20-25 kg were selected to study the therapeutic effect of n-isopropylacrylamide magnetic nanoparticles (NIPA-co-MN) on atrial fibrillation, and statistical analysis was performed. The volume and number of new neurons in the anterior right fat pad of atrium of test group were larger than the control group. The test group dogs produced 45 brand-new lncRNA, including 15 up-regulated transcripts and 30 down-regulated transcripts. MNPs injection can slow down the reduction of ventricular rate in right inferior ganglion plexus. The anterior right ganglion plexus resulted in a reduced amplitude of sinus tachyarrhythmia. This study provided references for the discovery of new diagnostic biomarkers or therapeutic targets and for the treatment of patients with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: